



Notice to Covered Entities

March 1, 2022

Effective April 1, 2022, IMBRUVICA® will be subject to the terms of AbbVie's 340B program integrity initiative designed to address prohibited and improper duplicate discounting on AbbVie products. As previously stated, this initiative does *not* block access to 340B priced medicines for any covered entity of the 340B program and patients continue to have uninterrupted access to AbbVie's medicines.

For help with the registration, account setup, and data submission process covered entities may access a repository of webinars at www.340BESP.com/resources/webinars or call Second Sight Solutions at 888-398-5520. Any changes to AbbVie's policy will be available in the most up-to-date policy document on www.340BESP.com. For other questions about AbbVie's 340B program integrity initiative, please direct communications to 340BCommunications@abbvie.com. For any questions specific to Imbruvica, please direct communications to Pharmacyclics, an AbbVie Company, at PCYC340BCommunications@pcyc.com.



AbbVie 340B Contract Pharmacy Data Integrity Initiative Applicable Products

PRODUCT
ANDROGEL®
CREON®
DEPAKOTE®
DUOPA®
GENGRAF®
HUMIRA®
IMBRUVICA®*
KALETRA®
K-TAB®
LUPRON®
MAVYRET®
NIASPAN®
NIMBEX®
NORVIR®
ORIAHNN®
ORLISSA®
RINVOQ®
SYNTHROID®
SKYRIZI®
SURVANTA®
TRICOR®
TRILIPIX®
ULTANE®
VIEKIRA PAK®
ZEMPLAR®

*340B Integrity Initiative will become effective for Imbruvica on April 1, 2022.